PDF(Pubmed)
Abstract：
UNASSIGNED: Probiotics are live microbial supplements that improve the microbial balance in the host animal when administered in adequate amounts. They play an important role in relieving symptoms of many diseases associated with gastrointestinal tract, for example, in necrotizing enterocolitis (NEC), antibiotic-associated diarrhea, relapsing Clostridium difficile colitis, Helicobacter pylori infections, and inflammatory bowel disease (IBD). In this narrative review, the authors aim to evaluate the role of different probiotic formulations in treating gastrointestinal diseases in pediatric population aged 18 years or younger and highlight the main considerations for selecting probiotic formulations for use in this population.
UNASSIGNED: The authors searched PubMed and Clinicaltrials.gov from inception to 24th July 2022, without any restrictions. Using an iterative process, the authors subsequently added papers through hand-searching citations contained within retrieved articles and relevant systematic reviews and meta-analyses.
UNASSIGNED: The effectiveness of single-organism and composite probiotics in treating gastrointestinal disorders in pediatric patients aged 18 or under were analyzed and compared in this study. A total of 39 studies were reviewed and categorized based on positive and negative outcomes, and compared with a placebo, resulting in 25 studies for single-organism and 14 studies for composite probiotics. Gastrointestinal disorders studied included NEC, acute gastroenteritis (AGE), Acute Diarrhea, Ulcerative Colitis (UC), and others. The results show that probiotics are effective in treating various gastrointestinal disorders in children under 18, with single-organism probiotics demonstrating significant positive outcomes in most studies, and composite probiotics showing positive outcomes in all studies analyzed, with a low incidence of negative outcomes for both types.
UNASSIGNED: This study concludes that single-organism and composite probiotics are effective complementary therapies for treating gastrointestinal disorders in the pediatric population. Hence, healthcare professionals should consider using probiotics in standard treatment regimens, and educating guardians can enhance the benefits of probiotic therapy. Further research is recommended to identify the optimal strains and dosages for specific conditions and demographics. The integration of probiotics in clinical practice and ongoing research can contribute to reducing the incidence and severity of gastrointestinal disorders in pediatric patients.
UNASSIGNED: The authors searched PubMed and Clinicaltrials.gov from inception to 24th July 2022, without any restrictions. Using an iterative process, the authors subsequently added papers through hand-searching citations contained within retrieved articles and relevant systematic reviews and meta-analyses.
UNASSIGNED: The effectiveness of single-organism and composite probiotics in treating gastrointestinal disorders in pediatric patients aged 18 or under were analyzed and compared in this study. A total of 39 studies were reviewed and categorized based on positive and negative outcomes, and compared with a placebo, resulting in 25 studies for single-organism and 14 studies for composite probiotics. Gastrointestinal disorders studied included NEC, acute gastroenteritis (AGE), Acute Diarrhea, Ulcerative Colitis (UC), and others. The results show that probiotics are effective in treating various gastrointestinal disorders in children under 18, with single-organism probiotics demonstrating significant positive outcomes in most studies, and composite probiotics showing positive outcomes in all studies analyzed, with a low incidence of negative outcomes for both types.
UNASSIGNED: This study concludes that single-organism and composite probiotics are effective complementary therapies for treating gastrointestinal disorders in the pediatric population. Hence, healthcare professionals should consider using probiotics in standard treatment regimens, and educating guardians can enhance the benefits of probiotic therapy. Further research is recommended to identify the optimal strains and dosages for specific conditions and demographics. The integration of probiotics in clinical practice and ongoing research can contribute to reducing the incidence and severity of gastrointestinal disorders in pediatric patients.
摘要：
益生菌是活的微生物补充剂,当以足够的量施用时,其改善宿主动物中的微生物平衡。它们在缓解与胃肠道相关的许多疾病的症状中起着重要作用，例如,坏死性小肠结肠炎（NEC），抗生素相关性腹泻,复发性艰难梭菌结肠炎，幽门螺杆菌感染,和炎症性肠病（IBD）。在这篇叙述性评论中，作者旨在评估不同益生菌制剂在18岁以下儿科人群胃肠道疾病治疗中的作用,并强调选择用于该人群的益生菌制剂的主要考虑因素.
■作者从成立到2022年7月24日搜索了PubMed和Clinicaltrials.gov，没有任何限制。使用迭代过程，作者随后通过手工检索检索到的文章中包含的引文以及相关的系统综述和荟萃分析来添加论文.
■在这项研究中，分析并比较了单生物和复合益生菌治疗18岁或以下儿科患者胃肠道疾病的有效性。共有39项研究进行了审查，并根据积极和消极的结果进行了分类。与安慰剂相比，导致25项单一生物研究和14项复合益生菌研究。研究的胃肠道疾病包括NEC，急性胃肠炎（AGE），急性腹泻,溃疡性结肠炎(UC),和其他人。结果表明，益生菌可有效治疗18岁以下儿童的各种胃肠道疾病，单生物益生菌在大多数研究中显示出显著的积极结果。和复合益生菌在所有分析的研究中显示出积极的结果，两种类型的负面结果发生率都很低。
■本研究得出的结论是，单生物和复合益生菌是治疗儿科人群胃肠道疾病的有效补充疗法。因此，医疗保健专业人员应考虑在标准治疗方案中使用益生菌，和教育监护人可以提高益生菌治疗的好处。建议进一步研究以确定特定条件和人口统计学的最佳菌株和剂量。益生菌在临床实践和正在进行的研究中的整合可以有助于降低儿科患者胃肠道疾病的发生率和严重程度。
■作者从成立到2022年7月24日搜索了PubMed和Clinicaltrials.gov，没有任何限制。使用迭代过程，作者随后通过手工检索检索到的文章中包含的引文以及相关的系统综述和荟萃分析来添加论文.
■在这项研究中，分析并比较了单生物和复合益生菌治疗18岁或以下儿科患者胃肠道疾病的有效性。共有39项研究进行了审查，并根据积极和消极的结果进行了分类。与安慰剂相比，导致25项单一生物研究和14项复合益生菌研究。研究的胃肠道疾病包括NEC，急性胃肠炎（AGE），急性腹泻,溃疡性结肠炎(UC),和其他人。结果表明，益生菌可有效治疗18岁以下儿童的各种胃肠道疾病，单生物益生菌在大多数研究中显示出显著的积极结果。和复合益生菌在所有分析的研究中显示出积极的结果，两种类型的负面结果发生率都很低。
■本研究得出的结论是，单生物和复合益生菌是治疗儿科人群胃肠道疾病的有效补充疗法。因此，医疗保健专业人员应考虑在标准治疗方案中使用益生菌，和教育监护人可以提高益生菌治疗的好处。建议进一步研究以确定特定条件和人口统计学的最佳菌株和剂量。益生菌在临床实践和正在进行的研究中的整合可以有助于降低儿科患者胃肠道疾病的发生率和严重程度。
